Navigating 10 Analyst Ratings For Geron
Portfolio Pulse from Benzinga Insights
Geron (NASDAQ:GERN), a clinical-stage biopharmaceutical company, has received diverse analyst ratings over the last three months, with a total of 10 analysts offering perspectives ranging from bullish to bearish. The average 12-month price target for GERN is $5.3, with a high estimate of $10.00 and a low estimate of $4.00, indicating a 32.5% increase from the previous average target of $4.00. Geron's financial performance shows challenges in revenue growth, profitability, and asset utilization, with a significant decline in revenue and below-average net margin, ROE, and ROA.
April 29, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron has been the subject of diverse analyst ratings, with an updated average 12-month price target of $5.3, reflecting a 32.5% increase. Financial challenges include a significant revenue decline and below-average profitability metrics.
The mixed analyst ratings with a higher average price target suggest optimism about Geron's future stock performance, despite its current financial challenges. The bullish sentiment from analysts, combined with the significant increase in the price target, could lead to short-term positive momentum in GERN's stock price. However, the underlying financial difficulties, such as the revenue decline and poor profitability metrics, may temper long-term gains unless addressed.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100